Mallinckrodt to acquire Therakos to expand hospital growth platform

US drugmaker Mallinckrodt (NYSE: MNK) has entered into a definitive agreement to acquire Therakos, immunotherapy company owned by investment firm Gores Group in a transaction valued at around $1.325 billion.

Subject to customary closing conditions, the parties expect the transaction to be completed in the latter part of the third calendar quarter of 2015, Mallinckrodt's fourth fiscal quarter.

This is the second major acquisition for Mallinckrodt this year; earlier, it entered into an agreement to acquire Ikaria, a privately-held critical care company, from a Madison Dearborn-led investor group in a transaction valued at around $2.3 billion (The Pharma Letter March 5).